Medscape1 天
EGF Receptor Tyrosine Kinase Inhibitors in the Treatment of Brain Metastases From Non-small ...
EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...
Nature10 个月
Optimal first-line therapy for NSCLC with EGFR mutations
The optimal selection of patients with non-small-cell lung cancer (NSCLC) for treatment with oral small-molecule tyrosine kinase inhibitors (TKIs) has been an area of great debate. Inhibiting EGFR ...
腾讯网6 天
突破 EGFR-TKI 耐药困境，Dato-DXd 关键研究汇总分析入选 LBA，将亮相 ESMO ...
2024 年 12 月 6 日 - 8 日，欧洲肿瘤内科学会亚洲年会（ESMO Asia）将在新加坡盛大召开。本届会议将汇聚全球专家学者，集中展示和讨论肿瘤学领域的最新科学和临床进展，为肿瘤领域带来一场学术盛宴。此次会议中，「Dato-DXd ...
生物通6 天
我国学者在肺癌脑转移靶向治疗耐药研究方面取得进展
在国家自然科学基金项目（批准号：82072784、82072785、82273304、82303437）等资助下，复旦大学附属华山医院毛颖教授、花玮教授和迟喻丹研究员团队在免疫逃逸参与肺癌脑转移靶向治疗耐药研究方面取得进展。研究成果以“通过CTLA4 ...
MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or ...
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
Cure Today12 天
Radiotherapy and EGFR-TKIs May Improve Treatment Outcomes in Lung Cancer
CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...
Medpage Today on MSN11 天
Treatment of Oligometastatic EGFR-Mutant Lung Cancer
EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, ...
Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients ...